How does myTomorrows support expanded access programs?

raymond.vanderwaal@mytomorrows.com 12 Jan 2024

1 mins read

share this post

We guide BioPharma companies through developing expanded access strategies up to full EAP execution and preparation for full commercial launch. We have experience in a wide range of expanded access use cases, across different regions and therapeutics areas:

free-of-charge or paid-for
single patient or cohort programs
post-trial access

Conducting expanded access programs on behalf of our clients is our core expertise. Our team of experts handles areas such as Regulatory, Quality, Site Management, Supply Chain, Real-World Data, and Pharmacovigilance.

share this post

raymond.vanderwaal@mytomorrows.com 12 Jan 2024

more articles

view all blogs

myTomorrows and Clínica Universidad de Navarra Partner to Advance AI-Powered Clinical Trial Infrastructure in Spain

myTomorrows Team

26 Mar 2026

5 mins read

Theo Cantero, Patient Navigator at myTomorrows

Supporting People with Brain Tumours: An Interview with Theo Cantero, Patient Navigator at myTomorrows

Andrea Enguita

25 Mar 2026

8 mins read

Michel van Harten AWS Pioneers

myTomorrows Joins AWS Pioneers Project 2026

myTomorrows Team

18 Mar 2026

7 mins read

myTomorrows Trust Center blog

myTomorrows Trust Center: Security, Compliance, and Transparency

Filippo Mandrini

19 Feb 2026

9 mins read

Man with ALS performing physical therapy

The Role of Physical Therapy in ALS Care

Andrea Enguita

14 Jan 2026

16 mins read

Medical researchers

Sentynl Selects myTomorrows to Lead Managed Access Program

myTomorrows Team

15 Dec 2025

4 mins read

Whitepaper: Advancing Neuro-Oncology Clinical Trial Access

Daniël Groeneweg

27 Nov 2025

8 mins read

Person with end-stage Parkinson's and caregiver

End-Stage Parkinson’s Disease: Symptoms, Care, and Support

Andrea Enguita

18 Nov 2025

21 mins read

Getting Started: myTomorrows Referral Platform for Site Staff

Adrianne Rivard

14 Nov 2025

10 mins read

myTomorrows Avego finding announcement

Our next chapter: €25M growth investment to scale patient access worldwide

Michel van Harten

11 Nov 2025

7 mins read